Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Non-Current Deffered Revenue (2016 - 2023)

Plus Therapeutics (PSTV) has disclosed Non-Current Deffered Revenue for 12 consecutive years, with $1.9 million as the latest value for Q4 2023.

  • Quarterly Non-Current Deffered Revenue rose 17.1% to $1.9 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2023, up 17.1% year-over-year, with the annual reading at $1.9 million for FY2023, 17.1% up from the prior year.
  • Non-Current Deffered Revenue for Q4 2023 was $1.9 million at Plus Therapeutics, up from $1.6 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $1.9 million in Q4 2023, with the low at $142000.0 in Q1 2019.
  • Average Non-Current Deffered Revenue over 3 years is $1.2 million, with a median of $1.6 million recorded in 2022.
  • The sharpest move saw Non-Current Deffered Revenue soared 35.24% in 2019, then increased 17.1% in 2023.
  • Over 3 years, Non-Current Deffered Revenue stood at $142000.0 in 2019, then surged by 1057.04% to $1.6 million in 2022, then rose by 17.1% to $1.9 million in 2023.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $1.9 million, $1.6 million, and $142000.0 for Q4 2023, Q4 2022, and Q1 2019 respectively.